XML 47 R36.htm IDEA: XBRL DOCUMENT v3.25.2
Segment Information (Tables)
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Information regarding industry segments at June 30, 2025 and 2024 and for the three months then ended are as follows (in millions):
Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2025$262.8 $388.8 $— 
 2024$250.5 $388.0 $— 
Cost of goods sold
2025$114.5 $191.8 $— 
2024$105.9 $177.5 $— 
Depreciation and amortization
2025$17.8 $22.8 $— 
2024$16.3 $20.1 $— 
Segment profit
2025$148.3 $197.0 $— 
 2024$144.6 $210.5 $— 
Segment assets
2025$309.8 $489.0 $— 
2024$308.8 $495.0 $— 
Information regarding industry segments for the six months ended June 30, 2025 and 2024 are as follows (in millions):
Life
Science
Clinical
Diagnostics
Other
Operations
Net sales2025$491.4 $745.6 $— 
 2024$492.2 $756.6 $0.5 
Cost of goods sold
2025$214.7 $371.0 $— 
2024$215.9 $351.7 $0.6 
Depreciation and amortization
2025$34.8 $43.9 $— 
2024$32.5 $41.0 $— 
Segment profit
2025$276.7 $374.6 $— 
 2024$276.3 $404.9 $(0.1)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated
The following reconciles total segment gross profit to consolidated income (loss) before income taxes (in millions):
Three Months EndedSix Months Ended
June 30,June 30,
 2025202420252024
Total segment profit
$345.3 $355.1 $651.3 $681.1 
Selling, general and administrative expense
(207.7)(194.7)(416.5)(409.6)
Research and development expense
(60.5)(58.9)(134.0)(125.3)
Interest expense(12.6)(12.3)(24.6)(24.5)
Foreign currency exchange (gains) losses, net(1.1)1.7 1.6 3.7 
Gains (losses) from change in fair market value of equity securities and loan receivable
334.4 (2,895.4)366.2 (2,473.2)
Other income, net16.2 18.2 53.4 52.6 
Consolidated income (loss) before income taxes
$414.0 $(2,786.3)$497.4 $(2,295.2)